An Improved LC-MS/MS Method for the Analysis of Thirteen Cytostatics on Workplace Surfaces.
Maria Francisca Portilha-CunhaSara RamosAdrián M T SilvaPedro NortonArminda AlvesMónica S F SantosPublished in: Pharmaceuticals (Basel, Switzerland) (2021)
Cytostatics are drugs used in cancer treatment, which pose serious risks to healthcare workers. Dermal absorption via surface contamination is the key exposure route; thus, rapid, reliable, and validated analytical methods for multicomponent detection are crucial to identify the exposure risk. A surface-wipe-sampling technique compatible with hospitals' safety requirements (gauze, 1 mL isopropanol) and a fast and simple extraction method (1 mL acetonitrile, 20 min ultrasonic bath, evaporation, reconstitution in 200 µL acetonitrile), coupled with liquid chromatography-tandem mass spectrometry analysis, were developed. It allowed identification and quantification of 13 cytostatics on surfaces: cyclophosphamide, doxorubicin, etoposide, ifosfamide, paclitaxel, bicalutamide, capecitabine, cyproterone, flutamide, imatinib, megestrol, mycophenolate mofetil, prednisone. Good linearity, sensitivity, and precision were achieved (R2 > 0.997, IDLs < 4.0 pg/cm2, average CV 16%, respectively). Accuracy for four model surfaces (melamine-coated wood, phenolic compact, steel 304, steel 316) was acceptable (80 ± 12%), except for capecitabine and doxorubicin. Global uncertainty is below 35% for concentrations above 100 pg/cm2 (except for capecitabine and doxorubicin)-a guidance value for relevant contamination. Method application in a Portuguese university hospital (28 samples) identified the presence of seven cytostatics, at concentrations below 100 pg/cm2, except for three samples. The widespread presence of cyclophosphamide evinces the necessity to review implemented procedures.
Keyphrases
- liquid chromatography tandem mass spectrometry
- simultaneous determination
- phase ii study
- drug delivery
- locally advanced
- metastatic breast cancer
- biofilm formation
- human health
- cancer therapy
- metastatic colorectal cancer
- loop mediated isothermal amplification
- risk assessment
- phase iii
- solid phase extraction
- high dose
- low dose
- drinking water
- ms ms
- health risk
- healthcare
- liquid chromatography
- rectal cancer
- molecularly imprinted
- open label
- staphylococcus aureus
- clinical trial
- tandem mass spectrometry
- squamous cell carcinoma
- mass spectrometry
- pseudomonas aeruginosa
- randomized controlled trial
- radiation therapy
- chronic myeloid leukemia
- cystic fibrosis
- escherichia coli
- sensitive detection
- health promotion
- climate change
- gas chromatography
- high resolution mass spectrometry